Clinical trials: Obese Subjects
Hypertension
Testing the Efficacy of Different Dosages of Lercanidipine to Reduce Hypertensive Blood Pressure in Normal Weight and Obese Patients
A double blind study to examine the safety and efficacy of different dosages of lercanidipine in normal weight and obese patients with hypertension
- Trial name
- NCT00160498
- Testing
- Lercanidipine
- Volunteers
- 180 people
- Sponsor
- UCB Pharma
Metabolism and Nutrition Disorders, Overweight or Obesity
A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese
The study is investigating new medicines for weight control in people with high body weight. The study looks at how the study medicines work in the body.
- Trial name
- NCT03574584
- Testing
- NNC0165-1562, Semaglutide
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Novo Nordisk A/S
Hypercholesterolemia, Dyslipidaemias
An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation
The investigational drugs administered in this study activate proteins called PPARs. Data in the scientific literature on PPARs, as well as animal data and early clinical data generated by GSK with these drugs, suggest that…
- Conditions
- Hypercholesterolemia, Dyslipidaemias, Obesity
- Trial name
- NCT00388180
- Testing
- GW501516, GW590735
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obesity and Overweight
A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese
The study is looking at possible new medicines for weight control in people with high body weight. The study looks at how the new medicines work in the body. The study consists of two parts.
- Trial name
- NCT03707990
- Testing
- NNC0165-1875, Semaglutide
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy, safety, PK and PD characteristics of different doses of TG103 injection in overweight/obese subjects with type 2 diabetes mellitus.
- Trial name
- NCT05063253
- Testing
- TG103
- Volunteers
- 208 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Obesity
A Study to Determine the Effects of TM30339 on Weight Loss in Obese Individuals.
The purpose of this study is to determine the effects of TM30339 on weight loss in obese individuals after 28 days dosing.
- Trial name
- NCT00746824
- Volunteers
- 192 people
- Sponsor
- 7TM Pharma A/S
Metabolic Syndrome, Overweight
Trial of Two Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome
The objective of this study was to investigate from 3 sites (University of Connecticut, University of Florida, and University of California, Irvine) whether enhancement of a modified Mediterranean-style, low glycemic load diet…
- Conditions
- Metabolic Syndrome, Overweight, Obesity, Hypercholesterolemia
- Trial name
- HMS4 (NCT01010841)
- Testing
- UltraMealPlus 360 (Medical food), Low-glycemic-load diet
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- MetaProteomics LLC
Obesity, Overweight
A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program
The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in treating obesity and leads to greater weight loss when given with a group lifestyle modification program…
- Trial name
- NCT00456521
- Testing
- Naltrexone SR 32 mg/ bupropion SR 360 mg/ day, Intensive group lifestyle modification counseling
- Where
- 9 sites in United States
- Volunteers
- 793 people
- Sponsor
- Orexigen Therapeutics, Inc
Overweight, Obesity
Safety and Efficacy of Litramine in Overweight and Obese Subjects
Preparations that bind to nutritional fat and inhibit its absorption could be decisively meaningful for the regulation of bodyweight or obesity.
- Conditions
- Overweight, Obesity, Weight Loss
- Trial name
- NCT01233349
- Testing
- Litramine
- Where
- Germany
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Obesity
First in Human Study in Subjects With Obesity, But Otherwise Healthy
This is a First in Human study to evaluate the safety and tolerability of DA-1726 following single and multiple doses in participants with obesity, but otherwise healthy subjects.
- Trial name
- NCT06252220
- Testing
- DA-1726
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Overweight and Obesity
Extension Study of Gelesis100 on Body Weight
This study is designed to assess the effect of Gelesis100 on body weight after an additional exposure of 24 weeks in subjects who completed the 24-week treatment period, and had at least 3% weight loss, in the Gelesis Loss Of…
- Trial name
- GLOW-EX (NCT03021291)
- Testing
- Gelesis100 (2.25 g)
- Where
- 16 sites in United States, Czechia and 3 more
- Volunteers
- 36 people
- Sponsor
- Gelesis, Inc.
Obesity
A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects
The purpose of this study was to assess the effect of naltrexone SR/bupropion SR (NB) on brain function in response to food cues using functional magnetic resonance imaging in overweight or obese subjects.
- Trial name
- NCT00711477
- Testing
- Naltrexone SR 32 mg/bupropion SR 360 mg/day, fMRI scan
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Orexigen Therapeutics, Inc
Metabolic Syndrome, Obesity
Pharmacodynamics and Pharmacokinetics of 3 New Developed Coated Glucose Beads in 20 Obese Healthy Subjects
This single-dose, randomized, open label, five-treatment, five-period, five-sequence crossover study was performed to assess pharmacodynamics (PD) and pharmacokinetics (PK) of three new developed coated Glucose beads formulations…
- Trial name
- NCT05713773
- Testing
- coated beads glucose (8 g) and caffeine anhydrous, coated beads glucose (8 g), uncoated beads glucose (8 g) and caffeine anhydrous
- Where
- Romania
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Aphaia Pharma US LLC
Obesity & Overweight
Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults
Muscle loss during caloric restriction is a significant concern for metabolic health and physical function, yet there is limited evidence on interventions that simultaneously target multiple contributing pathways.
- Trial name
- Redefine (NCT07447843)
- Testing
- Redefine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Nature's Sunshine Products, Inc.
Overweight and Obesity, PreDiabetes
Effects of Gelesis200 on Appetite Parameters, Food Intake, and Glycemic Control in Overweight or Obese Prediabetic Subjects: A Sub-Study of LIGHT-UP
This study evaluates the effects of Gelesis200 on Appetite Parameters, Food Intake, and Glycemic Control in Overweight or Obese Prediabetic Subjects: A Sub-Study of LIGHT-UP.
- Conditions
- Overweight and Obesity, PreDiabetes, Type2 Diabetes
- Trial name
- MATCH (NCT03622424)
- Testing
- Gelesis200
- Where
- Denmark
- Volunteers
- 16 people
- Sponsor
- Gelesis, Inc.
Morbid Obesity, Metabolic Disease
Study Evaluating Metabolic Syndrome in Subjects Undergoing Gastric Bypass Bariatric Syndrome
Metabolic syndrome is rapidly emerging as an epidemic of global proportions and its definition is still evolving. Patients with this syndrome are at increased risk for cardiovascular disease, and at increased risk of mortality…
- Trial name
- NCT00283374
- Testing
- Laparoscopic Roux-en-Y Gastric Bypass
- Where
- 17 sites in United States, Italy and 1 more
- Volunteers
- 120 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Neuromuscular Blockade
Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)
The purpose of this trial is to evaluate the safety and efficacy of Sugammadex when administered according to actual body weight (ABW) as compared to ideal body weight (IBW) for the reversal of both moderate and deep…
- Trial name
- NCT03346070
- Testing
- Sugammadex 2 mg/kg ABW, Sugammadex 2 mg/kg IBW, Sugammadex 4 mg/kg ABW
- Where
- 24 sites in United States, Austria and 3 more
- Volunteers
- 207 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity
A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)
The purpose of this study is to assess the effects of MK0557 on body weight in obese subjects.
- Trial name
- NCT00533598
- Testing
- MK0557
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Volunteers
A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects
PF-06427878 is a new compound proposed for the treatment of hyperlipidemia. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics after 2 weeks of dosing of PF-06427878 in…
- Trial name
- NCT02855177
- Testing
- PF-06427878
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Prediabetes
Explorative Assessment of Biomarkers in Overweight and Obese Subjects
The rationale for this trial is to apply a simple and minimally strenuous pre-screening approach prior to performing more extensive trial-specific screening and baseline-characterization activities in the resulting pre-selected…
- Trial name
- NCT01910051
- Where
- Germany
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH